Ultrasound-Mediated Delivery of RNA to Colonic Mucosa of Live Mice.

BACKGROUND & AIMS It is a challenge to deliver nucleic acids to gastrointestinal (GI) tissues due to their size and need for intracellular delivery. They are also extremely susceptible to degradation by nucleases, which are ubiquitous in the GI tract. We investigated whether ultrasound, which can permeabilize tissue through a phenomenon known as transient cavitation, can be used to deliver RNA to the colonic mucosa of living mice. METHODS We investigated delivery of fluorescently labeled permeants to colon tissues of Yorkshire pigs ex vivo and mice in vivo. Colon tissues were collected and fluorescence was measured by confocal microscopy. We then evaluated whether ultrasound is effective in delivering small interfering (si)RNA to C57BL/6 mice with dextran sodium sulfate-induced colitis. Some mice were given siRNA against tumor necrosis factor (Tnf) mRNA for 6 days; colon tissues were collected and analyzed histologically and TNF protein levels measured by enzyme-linked immunosorbent assay. Feces were collected and assessed for consistency and occult bleeding. We delivered mRNA encoding firefly luciferase to colons of healthy C57BL/6 mice. RESULTS Exposure of ex vivo pig colon tissues to 20 kHz ultrasound for 1 minute increased the level of delivery of 3 kDa dextran 7-fold compared with passive diffusion (P = .037); 40 kHz ultrasound application for 0.5 seconds increased the delivery 3.3-fold in living mice (P = .041). Confocal microscopy analyses of colon tissues from pigs revealed regions of punctuated fluorescent dextran signal, indicating intracellular delivery of macromolecules. In mice with colitis, ultrasound delivery of unencapsulated siRNA against Tnf mRNA reduced protein levels of TNF in colon tissues, compared with mice with colitis given siRNA against Tnf mRNA without ultrasound (P ≤ .014), and reduced features of inflammation (P ≤ 4.1 × 10-5). Separately, colons of mice administered an mRNA encoding firefly luciferase with ultrasound and the D-luciferin substrate had levels of bioluminescence 11-fold greater than colons of mice given the mRNA alone (P = .0025). Ultrasound exposures of 40 kHz ultrasound for 0.5 seconds were well tolerated, even in mice with acute colitis. CONCLUSIONS Ultrasound can be used to deliver mRNAs and siRNAs to the colonic mucosa of mice and knock down expression of target mRNAs.

[1]  Giovanni Traverso,et al.  Low-frequency ultrasound for drug delivery in the gastrointestinal tract , 2016, Expert opinion on drug delivery.

[2]  R. Klopfleisch,et al.  Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation in vivo. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Mohammad Ariful Islam,et al.  Biomaterials for mRNA delivery. , 2015, Biomaterials science.

[4]  Daniel G. Anderson,et al.  Ultrasound-mediated gastrointestinal drug delivery , 2015, Science Translational Medicine.

[5]  T. Murdoch,et al.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target , 2015, The American Journal of Gastroenterology.

[6]  Maria Fichera,et al.  Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. , 2015, The New England journal of medicine.

[7]  Samir Mitragotri,et al.  Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies , 2014, Nature Reviews Drug Discovery.

[8]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[9]  L. Fändriks,et al.  Surface area of the digestive tract – revisited , 2014, Scandinavian journal of gastroenterology.

[10]  Markus F. Neurath,et al.  Cytokines in inflammatory bowel disease , 2014, Nature Reviews Immunology.

[11]  Robert Langer,et al.  Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates , 2014, Proceedings of the National Academy of Sciences.

[12]  Robert Langer,et al.  A vector-free microfluidic platform for intracellular delivery , 2013, Proceedings of the National Academy of Sciences.

[13]  Hollis G. Potter,et al.  Author Manuscript , 2013 .

[14]  T. Schlake,et al.  Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection , 2012, Nature Biotechnology.

[15]  Laura M Ensign,et al.  Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. , 2012, Advanced drug delivery reviews.

[16]  P. Uzor,et al.  Transdermal Drug Delivery , 2012 .

[17]  Gaurav Sahay,et al.  Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. , 2012, Journal of the American Chemical Society.

[18]  E. Szigethy,et al.  Inflammatory bowel disease. , 2011, Pediatric clinics of North America.

[19]  R. Langer,et al.  Low-frequency sonophoresis: application to the transdermal delivery of macromolecules and hydrophilic drugs , 2010, Expert opinion on drug delivery.

[20]  Didier Merlin,et al.  Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. , 2010, Nature materials.

[21]  Vincent M Rotello,et al.  Intracellular delivery of a membrane-impermeable enzyme in active form using functionalized gold nanoparticles. , 2010, Journal of the American Chemical Society.

[22]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[23]  L. Hale,et al.  Treatment of experimental colitis in mice with LMP-420, an inhibitor of TNF transcription , 2008, Journal of Inflammation.

[24]  D. Teitelbaum,et al.  Colostomy: formation and closure , 2006 .

[25]  Mark R Prausnitz,et al.  Mechanism of intracellular delivery by acoustic cavitation. , 2006, Ultrasound in medicine & biology.

[26]  B. Baker,et al.  Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[27]  G. Devi,et al.  siRNA-based approaches in cancer therapy , 2006, Cancer Gene Therapy.

[28]  Thierry Bettinger,et al.  Plasma membrane poration induced by ultrasound exposure: implication for drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[29]  S. V. van Deventer,et al.  A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis , 2004, Gut.

[30]  A. Gewirtz,et al.  Alicaforsen. Isis Pharmaceuticals. , 2001, Current opinion in investigational drugs.

[31]  T. Macdonald,et al.  Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. , 2001, The Journal of clinical investigation.

[32]  C. Fiocchi,et al.  TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. , 2001, The Journal of clinical investigation.

[33]  C. Heldin,et al.  Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling , 1997, Nature.

[34]  C. Heldin,et al.  Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. , 1997, Nature.

[35]  H. Cooper,et al.  Clinicopathologic study of dextran sulfate sodium experimental murine colitis. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[36]  D. Podolsky,et al.  Inflammatory bowel disease (1) , 1991, The New England journal of medicine.

[37]  R E Apfel,et al.  Thresholds for transient cavitation produced by pulsed ultrasound in a controlled nuclei environment. , 1989, The Journal of the Acoustical Society of America.

[38]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.

[39]  C. FordAlexander,et al.  ULCERATIVE colitis. , 1997, Journal of the American Medical Association.